The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Jan 2003Cited by 454 (Europe PMC)

PMID12510800DOI10.1359/jbmr.2003.18.1.9PepBankPUB-12510800

Publisher page PubMedAsk about this study

Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

13 results from studies that gave the peptide. 13 results from people.

01HumanRandomized controlled trialMechanism
In men with osteoporosis, teriparatide increased biochemical bone formation markers early during therapy.
In plain wordsIn men with osteoporosis, bone formation markers increased during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone formation markers
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · injection · Median 11 monthsAs given in this study (human).
Source sentences
Summary
Biochemical markers of bone formation increased early in the course of therapy and were followed by increases in indices of osteoclastic activity.
3 context sentences(design, population, supporting numbers)
Summary · context
We randomized 437 men with spine or hip bone mineral density more than 2 SD below the young adult male mean to daily injections of placebo, teriparatide 20 microg, or teriparatide 40 microg.
Summary · context
All subjects also received supplemental calcium and vitamin D.
Summary · context
The study was stopped after a median duration of 11 months because of a finding of osteosarcomas in rats in routine toxicology studies.
Report a problemFND-1251080001
02HumanRandomized controlled trialMechanism
In men with osteoporosis, increases in osteoclastic activity indices followed increases in bone formation markers during teriparatide therapy.
In plain wordsIn men with osteoporosis, bone breakdown activity increased after bone formation markers increased during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseOsteoclastic activity indices
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · injection · Median 11 monthsAs given in this study (human).
Source sentences
Summary
Biochemical markers of bone formation increased early in the course of therapy and were followed by increases in indices of osteoclastic activity.
3 context sentences(design, population, supporting numbers)
Summary · context
We randomized 437 men with spine or hip bone mineral density more than 2 SD below the young adult male mean to daily injections of placebo, teriparatide 20 microg, or teriparatide 40 microg.
Summary · context
All subjects also received supplemental calcium and vitamin D.
Summary · context
The study was stopped after a median duration of 11 months because of a finding of osteosarcomas in rats in routine toxicology studies.
Report a problemFND-1251080002
03HumanRandomized controlled trialEfficacy outcome
In men with osteoporosis, spine bone mineral density exceeded placebo after three months of teriparatide treatment.
In plain wordsIn men with osteoporosis, teriparatide increased spine bone density compared with placebo at the early assessment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSpine bone mineral density at early assessment
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · injection · 3 monthsAs given in this study (human).
Source sentences
Summary
Spine bone mineral density was greater than in placebo subjects after 3 months of teriparatide therapy, and by the end of therapy it was increased by 5.9% (20 microg) and 9.0% (40 microg) above baseline (p < 0.001 vs. placebo for both comparisons).
3 context sentences(design, population, supporting numbers)
Summary · context
We randomized 437 men with spine or hip bone mineral density more than 2 SD below the young adult male mean to daily injections of placebo, teriparatide 20 microg, or teriparatide 40 microg.
Summary · context
All subjects also received supplemental calcium and vitamin D.
Summary · context
The study was stopped after a median duration of 11 months because of a finding of osteosarcomas in rats in routine toxicology studies.
Report a problemFND-1251080003
04HumanRandomized controlled trialEfficacy outcome
In men with osteoporosis, lower-dose teriparatide increased spine bone mineral density by 5.9% from baseline, significantly more than placebo.
In plain wordsIn men with osteoporosis, lower-dose teriparatide increased spine bone density more than placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSpine bone mineral density, lower dose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · injection · Median 11 monthsAs given in this study (human).
Measurements
Spine BMD increase
5.9%
20 microg, above baseline
Source sentences
Summary
Spine bone mineral density was greater than in placebo subjects after 3 months of teriparatide therapy, and by the end of therapy it was increased by 5.9% (20 microg) and 9.0% (40 microg) above baseline (p < 0.001 vs. placebo for both comparisons).
3 context sentences(design, population, supporting numbers)
Summary · context
We randomized 437 men with spine or hip bone mineral density more than 2 SD below the young adult male mean to daily injections of placebo, teriparatide 20 microg, or teriparatide 40 microg.
Summary · context
All subjects also received supplemental calcium and vitamin D.
Summary · context
The study was stopped after a median duration of 11 months because of a finding of osteosarcomas in rats in routine toxicology studies.
Report a problemFND-1251080004
05HumanRandomized controlled trialEfficacy outcome
In men with osteoporosis, higher-dose teriparatide increased spine bone mineral density by 9.0% from baseline, significantly more than placebo.
In plain wordsIn men with osteoporosis, higher-dose teriparatide increased spine bone density more than placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSpine bone mineral density, higher dose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg daily · injection · Median 11 monthsAs given in this study (human).
Measurements
Spine BMD increase
9%
40 microg, above baseline
Source sentences
Summary
Spine bone mineral density was greater than in placebo subjects after 3 months of teriparatide therapy, and by the end of therapy it was increased by 5.9% (20 microg) and 9.0% (40 microg) above baseline (p < 0.001 vs. placebo for both comparisons).
3 context sentences(design, population, supporting numbers)
Summary · context
We randomized 437 men with spine or hip bone mineral density more than 2 SD below the young adult male mean to daily injections of placebo, teriparatide 20 microg, or teriparatide 40 microg.
Summary · context
All subjects also received supplemental calcium and vitamin D.
Summary · context
The study was stopped after a median duration of 11 months because of a finding of osteosarcomas in rats in routine toxicology studies.
Report a problemFND-1251080005
06HumanRandomized controlled trialEfficacy outcome
In men with osteoporosis, lower-dose teriparatide increased femoral neck bone mineral density by 1.5% above baseline.
In plain wordsIn men with osteoporosis, lower-dose teriparatide increased femoral neck bone density compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck bone mineral density, lower dose
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · injection · Median 11 monthsAs given in this study (human).
Measurements
Femoral neck BMD increase
1.5%
20 microg, above baseline
Source sentences
Summary
Femoral neck bone mineral density increased 1.5% (20 microg; p = 0.029) and 2.9% (40 microg; p < 0.001), and whole body bone mineral content increased 0.6% (20 microg; p = 0.021) and 0.9% (40 microg;p = 0.005) above baseline in the teriparatide subjects.
3 context sentences(design, population, supporting numbers)
Summary · context
We randomized 437 men with spine or hip bone mineral density more than 2 SD below the young adult male mean to daily injections of placebo, teriparatide 20 microg, or teriparatide 40 microg.
Summary · context
All subjects also received supplemental calcium and vitamin D.
Summary · context
The study was stopped after a median duration of 11 months because of a finding of osteosarcomas in rats in routine toxicology studies.
Report a problemFND-1251080006
07HumanRandomized controlled trialEfficacy outcome
In men with osteoporosis, higher-dose teriparatide increased femoral neck bone mineral density by 2.9% above baseline.
In plain wordsIn men with osteoporosis, higher-dose teriparatide increased femoral neck bone density compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck bone mineral density, higher dose
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg daily · injection · Median 11 monthsAs given in this study (human).
Measurements
Femoral neck BMD increase
2.9%
40 microg, above baseline
Source sentences
Summary
Femoral neck bone mineral density increased 1.5% (20 microg; p = 0.029) and 2.9% (40 microg; p < 0.001), and whole body bone mineral content increased 0.6% (20 microg; p = 0.021) and 0.9% (40 microg;p = 0.005) above baseline in the teriparatide subjects.
3 context sentences(design, population, supporting numbers)
Summary · context
We randomized 437 men with spine or hip bone mineral density more than 2 SD below the young adult male mean to daily injections of placebo, teriparatide 20 microg, or teriparatide 40 microg.
Summary · context
All subjects also received supplemental calcium and vitamin D.
Summary · context
The study was stopped after a median duration of 11 months because of a finding of osteosarcomas in rats in routine toxicology studies.
Report a problemFND-1251080007
08HumanRandomized controlled trialEfficacy outcome
In men with osteoporosis, lower-dose teriparatide increased whole-body bone mineral content by 0.6% above baseline.
In plain wordsIn men with osteoporosis, lower-dose teriparatide increased whole-body bone mineral content compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseWhole-body bone mineral content, lower dose
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · injection · Median 11 monthsAs given in this study (human).
Measurements
Bone mineral content increase
0.6%
20 microg, above baseline
Source sentences
Summary
Femoral neck bone mineral density increased 1.5% (20 microg; p = 0.029) and 2.9% (40 microg; p < 0.001), and whole body bone mineral content increased 0.6% (20 microg; p = 0.021) and 0.9% (40 microg;p = 0.005) above baseline in the teriparatide subjects.
3 context sentences(design, population, supporting numbers)
Summary · context
We randomized 437 men with spine or hip bone mineral density more than 2 SD below the young adult male mean to daily injections of placebo, teriparatide 20 microg, or teriparatide 40 microg.
Summary · context
All subjects also received supplemental calcium and vitamin D.
Summary · context
The study was stopped after a median duration of 11 months because of a finding of osteosarcomas in rats in routine toxicology studies.
Report a problemFND-1251080008
09HumanRandomized controlled trialEfficacy outcome
In men with osteoporosis, higher-dose teriparatide increased whole-body bone mineral content by 0.9% above baseline.
In plain wordsIn men with osteoporosis, higher-dose teriparatide increased whole-body bone mineral content compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseWhole-body bone mineral content, higher dose
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg daily · injection · Median 11 monthsAs given in this study (human).
Measurements
Bone mineral content increase
0.9%
40 microg, above baseline
Source sentences
Summary
Femoral neck bone mineral density increased 1.5% (20 microg; p = 0.029) and 2.9% (40 microg; p < 0.001), and whole body bone mineral content increased 0.6% (20 microg; p = 0.021) and 0.9% (40 microg;p = 0.005) above baseline in the teriparatide subjects.
3 context sentences(design, population, supporting numbers)
Summary · context
We randomized 437 men with spine or hip bone mineral density more than 2 SD below the young adult male mean to daily injections of placebo, teriparatide 20 microg, or teriparatide 40 microg.
Summary · context
All subjects also received supplemental calcium and vitamin D.
Summary · context
The study was stopped after a median duration of 11 months because of a finding of osteosarcomas in rats in routine toxicology studies.
Report a problemFND-1251080009
10HumanRandomized controlled trialEfficacy outcome
In men with osteoporosis, radial bone mineral density did not change during teriparatide treatment.
In plain wordsIn men with osteoporosis, teriparatide did not change radial bone density compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeRadial bone mineral density
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · injection · Median 11 monthsAs given in this study (human).
Source sentences
Summary
There was no change in radial bone mineral density in the teriparatide groups.
3 context sentences(design, population, supporting numbers)
Summary · context
We randomized 437 men with spine or hip bone mineral density more than 2 SD below the young adult male mean to daily injections of placebo, teriparatide 20 microg, or teriparatide 40 microg.
Summary · context
All subjects also received supplemental calcium and vitamin D.
Summary · context
The study was stopped after a median duration of 11 months because of a finding of osteosarcomas in rats in routine toxicology studies.
Report a problemFND-1251080010
11HumanRandomized controlled trialOther
In men with osteoporosis receiving teriparatide, the abstract reported expected mineral metabolism changes without specifying their direction.
In plain wordsIn men with osteoporosis receiving teriparatide, mineral metabolism changed, but the abstract did not specify how.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedMineral metabolism
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · injection · Median 11 monthsAs given in this study (human).
Source sentences
Summary
Subjects experienced expected changes in mineral metabolism.
3 context sentences(design, population, supporting numbers)
Summary · context
We randomized 437 men with spine or hip bone mineral density more than 2 SD below the young adult male mean to daily injections of placebo, teriparatide 20 microg, or teriparatide 40 microg.
Summary · context
All subjects also received supplemental calcium and vitamin D.
Summary · context
The study was stopped after a median duration of 11 months because of a finding of osteosarcomas in rats in routine toxicology studies.
Report a problemFND-1251080012
12HumanRandomized controlled trialSafety outcome
In men with osteoporosis, adverse events were similar with lower-dose teriparatide and placebo.
In plain wordsIn men with osteoporosis, lower-dose teriparatide and placebo had similar adverse event frequency.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeAdverse events, lower dose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
20 microg daily · injection · Median 11 monthsAs given in this study (human).
Source sentences
Summary
Adverse events were similar in the placebo and 20-microg groups, but more frequent in the 40-microg group.
3 context sentences(design, population, supporting numbers)
Summary · context
We randomized 437 men with spine or hip bone mineral density more than 2 SD below the young adult male mean to daily injections of placebo, teriparatide 20 microg, or teriparatide 40 microg.
Summary · context
All subjects also received supplemental calcium and vitamin D.
Summary · context
The study was stopped after a median duration of 11 months because of a finding of osteosarcomas in rats in routine toxicology studies.
Report a problemFND-1251080013
13HumanRandomized controlled trialSafety outcome
In men with low bone density, adverse events were more frequent with teriparatide 40 microg than in the placebo and 20-microg groups.
In plain wordsIn men with low bone density, adverse events were more frequent with teriparatide 40 microg than with placebo or 20 microg.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseAdverse events, higher dose versus placebo
Study
n: not reported in source
Comparator
Placebo and teriparatide 20 microg groups
Outcome group
Adverse events · Whole body
Studied dose
40 microg daily · injection · Median 11 monthsAs given in this study (human).
Source sentences
Summary
Adverse events were similar in the placebo and 20-microg groups, but more frequent in the 40-microg group.
3 context sentences(design, population, supporting numbers)
Summary · context
We randomized 437 men with spine or hip bone mineral density more than 2 SD below the young adult male mean to daily injections of placebo, teriparatide 20 microg, or teriparatide 40 microg.
Summary · context
All subjects also received supplemental calcium and vitamin D.
Summary · context
The study was stopped after a median duration of 11 months because of a finding of osteosarcomas in rats in routine toxicology studies.
Report a problemFND-1251080014

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

14HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In men with osteoporosis, teriparatide bone density responses were similar across gonadal status, age, baseline density, body mass, smoking, and alcohol intake.
In plain wordsIn men with osteoporosis, bone density responses to teriparatide were similar across the reported patient characteristics.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBone mineral density response across patient characteristics
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Bone mineral density responses to teriparatide were similar regardless of gonadal status, age, baseline bone mineral density, body mass index, smoking, or alcohol intake.
3 context sentences(design, population, supporting numbers)
Summary · context
We randomized 437 men with spine or hip bone mineral density more than 2 SD below the young adult male mean to daily injections of placebo, teriparatide 20 microg, or teriparatide 40 microg.
Summary · context
All subjects also received supplemental calcium and vitamin D.
Summary · context
The study was stopped after a median duration of 11 months because of a finding of osteosarcomas in rats in routine toxicology studies.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1251080011

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 not yet recruiting · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 1/2NCT06303284

PROactive HEALing in High-Risk Pelvic and Non-hip Lower Extremity Fragility Fractures (PRO HEAL Pilot)

University of Calgaryn = 54est. 15 Mar 2027 to est. 17 Mar 2031

Lower Extremity Fractures · Pelvis · Acetabulum

Trial page ClinicalTrials.govUpdated 6 Oct 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.